On September 4, 2026, Vogue Business published Amy Francombe's investigation into the vaginal-health category's rapid shift from neglected medical backwater to funded consumer-health vertical — and the risk that it becomes a status purchase before it becomes accessible care. The framing device is an April post by longevity entrepreneur Bryan Johnson, who published his girlfriend Kate Tolo's vaginal microbiome test results on X and declared she ranked in the "top 1% of all vaginas" with a score of 100 out of 100. Beneath the overshare, the piece argues, was evidence that the vaginal microbiome has finally entered mainstream conversation.

Why It Matters

For investors, this is the clearest public accounting yet of a vertical that has been assembling quietly: diagnostics (Evvy, Daye, Juno Bio), devices (LiviWell, Yon E Health), and therapeutics (Seed VS-01, Vaginal Biome Science), sitting on top of a documented $1.55B women's-health funding year. The thesis is unusually clean — a large patient population, a real clinical endpoint set spanning infections, infertility, preterm birth and cancer progression, and almost no legacy competition because the area was never properly studied. The risk flagged here is equally clean, and it is the one sexual-wellness founders should read twice. A category that monetizes on insecurity converts fast and churns faster, and it invites exactly the regulatory attention that "vagina-maxxing" style products have already drawn from gynecologists. Jain's line about wellness classification is the strategic point: framing vaginal health as wellness kept it cheap to enter and impossible to reimburse. The companies pushing toward CLIA-grade labs, clinician-ordered tests and peer-reviewed accuracy data are making a bet that the reimbursable, clinical version of this market is the durable one — and that price points north of $100 a test will not survive contact with the mainstream without it.

The funding picture Vogue assembles is concrete. New York-based Evvy, which offers metagenomic vaginal microbiome sequencing with clinician review, has raised more than $20 million and served over 100,000 patients in five years; its test runs $159, or $129 with membership. In 2025, Dutch startup Yon E Health raised €250,000 pre-seed for a device measuring vaginal pH and temperature, and US startup LiviWell raised $3.3 million for a device supporting vaginal microbiome health — the same LiviWell whose Livi post-intercourse absorption device received FDA 510(k) clearance in March 2026 and launched August 18. Across the broader category, the piece cites W Group data putting women's health companies at a record $1.55 billion in disclosed equity investment in 2025, up 41% year over year.

Evvy CEO and co-founder Priyanka Jain frames the research gap as self-reinforcing. "It comes down to stigma and a research gap, and the two reinforce each other in a vicious cycle," she told Vogue, noting that women were not required to be included in US clinical research until 1993. Her sharper argument is a category one: "I think it's a mistake that vaginal health has been treated as a wellness category for so long — that's probably part of why it's stayed so underfunded and underserved. Vaginal microbiome dysbiosis is a healthcare problem and deserves to be treated like one."

Daye takes a different route with a diagnostic tampon designed to collect fluid from inside the vaginal canal, developed to test for 25 markers spanning the microbiome, STIs and HPV, with a full screening kit at £99. Founder Valentina Milanova emphasized accessibility as a design constraint rather than a marketing line — the product was tested with first-time tampon users in South Asian communities, trans men, and people with learning disabilities, and its materials are written for a basic reading age across 12 languages. Elsewhere in the category, Seed has developed VS-01, a vaginal synbiotic with three proprietary Lactobacillus crispatus strains, and Vaginal Biome Science — founded by Good Clean Love's Wendy Strgar — is building microbiome-based therapies.

The warning in the piece is the one the intimate-care aisle has earned. Milanova is blunt about products promising to make vaginas smell like peaches or feel "like a virgin": "That isn't women empowerment. It takes an entirely normal body and creates a problem that women are then expected to spend money fixing." Euromonitor's Kayla Villena argues the category only scales if solutions land in familiar routines and trusted channels rather than as luxury optimizations, and The Future Laboratory's Alice Crossley cautions that venture capital should not turn an under-researched, highly personal area into a commercial-exploitation opportunity.

Sources

Update — 2026-09-05

{Initial entry — story first created.}